Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors
Eur J Intern Med. 2026 Sep 24:107193. doi: 10.1016/j.ejim.2026.107193. Online ahead of print.ABSTRACTFor many years risk-modifying therapy targeted individual aspects of CKM syndrome. Statins target dyslipidaemia and atherosclerotic risk (i.e. C&M), and renin-angiotensin-system (RAS) inhibitors targ

